CRUSHAGE: Evaluation of Rupture of Galenic Practices at Home in a Population Aged 65 or Older

Sponsor
University Hospital Center of Martinique (Other)
Overall Status
Completed
CT.gov ID
NCT03681899
Collaborator
(none)
289
1
15
19.3

Study Details

Study Description

Brief Summary

Elderly people frequently take several medications and are exposed to iatrogenic risks.

The oral route is the preferred route of administration. The effectiveness and the safety of the drugs depend in particular on the modes of administration (frequency of the intake, respect of the doses and the galenic ...).

However, these modalities are very little known concerning the treatments intake at home in the elderly population.

In a health facility welcoming geriatric patients, the rupture of galenic is frequent and favored by swallowing disorders, dependence, the increase in age, the presence of cognitive disorders or psycho-behavioral disorders.

The consequences of the rupture of galenic are numerous, concern the patients but also the caregivers who administer the treatments.

Condition or Disease Intervention/Treatment Phase
  • Other: Questionnaires

Detailed Description

Primary objective :
  • Estimate the rupture of galenic prevalence of at least one molecule in a population of subjects aged 65 years or over living at home and taking at least one oral drug for 2 weeks or more.
Secondary objectives:
  • Identify the drug classes most frequently involved in the rupture of galenic in a population of subjects aged 65 years of age or over at home;

  • Identify the actors of the drug administration in a population of subjects aged 65 years of or over at home;

  • To determine the medical and sociodemographic factors associated with the rupture of galenic in a population of subjects aged 65 years or over at home;

  • To determine the modalities of rupture of galenic in a population of subjects aged 65 or over at home.

Study Design

Study Type:
Observational
Actual Enrollment :
289 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Evaluation of Rupture of Galenic Practices at Home in a Population Aged 65 or Older
Actual Study Start Date :
Sep 18, 2018
Actual Primary Completion Date :
Dec 18, 2019
Actual Study Completion Date :
Dec 18, 2019

Arms and Interventions

Arm Intervention/Treatment
Subjects aged of 65 years or older

Subjects aged of 65 years or older, taking at least one oral medication for two weeks or more.

Other: Questionnaires
Socio-demographic data (age, sex, place of residence, and family status, last occupation, existence or not of a primary caregiver (family and / or professional)); Medical and surgical history (Charlson Comorbidity Scale); Assessment of oral/dental condition Record of drug treatments (number of oral medications per day, therapeutic class, number of daily intakes); Oral treatments intake modalities (galenic breakdown of one or more drugs, usual or occasional, modalities of rupture, person responsible for the drugs, mixing with food / drink); Autonomy evaluation (Lawton and Katz scales); Mobility assessment (anamnestic evaluation); Evaluation of Thyme (GDS 4 items); Psycho-behavioral disorders, Assessment of swallowing (presence of a diagnosis of dysphagia or suspicion based on anamnestic data).

Outcome Measures

Primary Outcome Measures

  1. Estimate the rupture of galenic prevalence of at least one molecule in a population of subjects aged 65 years or over living at home and taking at least one oral drug for 2 weeks or more. [12 months]

    Calculation of the prevalence of galenic rupture by dividing the number of persons with at least one rupture of galenic by the number of persons included in the study.

Secondary Outcome Measures

  1. To determine the drug classes most frequently involved in the rupture of galenic in a population of subjects aged 65 years of age or over at home [12 months]

    Number of participants for each drug class

  2. To determine the drug classes most frequently involved in the rupture of galenic in a population of subjects aged 65 years of age or over at home [12 months]

    Percentage of participants for each drug class

  3. To determine the actors of the drug administration in a population of subjects aged 65 years of or over at home [12 months]

    Number of participants for each actor

  4. To determine the actors of the drug administration in a population of subjects aged 65 years of or over at home [12 months]

    Percentage of participants for each actor

  5. To determine the medical and sociodemographic factors associated with the rupture of galenic in a population of subjects aged 65 years or over at home [12 months]

    Binary logistic regression with variable to explain, the rupture of galenic

  6. To determine the medical and sociodemographic factors associated with the rupture of galenic in a population of subjects aged 65 years or over at home [12 months]

    Binary logistic regression with variable as explanatory variables, the medical and sociodemographic factors

  7. To determine the modalities of rupture of galenic in a population of subjects aged 65 or over at home [12 months]

    Number of paticipants for each modality

  8. To determine the modalities of rupture of galenic in a population of subjects aged 65 or over at home [12 months]

    Percentage of paticipants for each modality

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Subjects aged 65 or over;

  • Patient taking at least one oral medication for two weeks or more;

  • Patient affiliated to a social security scheme;

  • Patient who has agreed to reply to the questionnaire or, in case of inability to agree, agreement obtained from the caregiver or guardian/curator.

Exclusion Criteria:
  • Patient unable to answer questionnaires and without a referent caregiver capable of reply ;

  • Patient having changed residence for two weeks or less;

  • Patient residing in a residential care facility for dependent elderly people.

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU de Martinique Fort-de-France Martinique France 97200

Sponsors and Collaborators

  • University Hospital Center of Martinique

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital Center of Martinique
ClinicalTrials.gov Identifier:
NCT03681899
Other Study ID Numbers:
  • 18_RIPH3-07
First Posted:
Sep 24, 2018
Last Update Posted:
Jul 10, 2020
Last Verified:
Oct 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital Center of Martinique
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 10, 2020